Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients-Reference-Cited by-同舟云学术

Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients

Published:2018-11-21 Issue:6 Volume:195 Page:468-474
ISSN:0179-7158
Container-title:Strahlentherapie und Onkologie
language:en
Short-container-title:Strahlenther Onkol

Author:

Elicin Olgun^ORCID,Sermaxhaj Burim,Bojaxhiu Beat,Shelan Mohamed,Giger Roland,Rauch Daniel,Aebersold Daniel M.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/content/pdf/10.1007/s00066-018-1400-5.pdf

Reference19 articles.

1. Pignon J‑P, le Maître A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14. https://doi.org/10.1016/j.radonc.2009.04.014

2. National Comprehensive Cancer Network (2018) National Comprehensive Cancer Network guidelines for head and neck cancers (version 1.2018). http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf . Accessed 28 Feb 2018

3. Grégoire V, Lefebvre J‑L, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v184–v186. https://doi.org/10.1093/annonc/mdq185

4. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28. https://doi.org/10.1016/S1470-2045(09)70311-0

5. Bourhis J, Sun xu S, Sire C, Tao Y, Martin L, Khoury C et al (2016) Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients with N0-N2a squamous cell carcinoma of the head and neck (SCCHN): results of the GORTEC 2007-01 phase III randomized trial. J Clin Oncol 34(15 suppl):6003

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic study of low-energy electron interactions in the fragmentation of cisplatin;Journal of Photochemistry and Photobiology A: Chemistry;2024-01

2. Risk of second primary cancer in patients with head and neck squamous cell carcinoma: a systemic review and meta-analysis;Clinical Oral Investigations;2023-08-04

3. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer – Results of a large multicenter analysis;Radiotherapy and Oncology;2023-04

4. Mechanistic Study of Low-Energy Electron Interactions in the Fragmentation of Cisplatin;2023

5. The Role of HPV in Determining Treatment, Survival, and Prognosis of Head and Neck Squamous Cell Carcinoma;Cancers;2022-09-03